{"preliminary_commentary":{"by_channel":{"x_thread":21,"youtube":1,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05197322\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["pembrolizumab"]],"indication":"high-risk stage 2 or 3 MMR-deficient colorectal cancer","name":"NEOPRISM-CRC","nct_id":"NCT05197322","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neoprism-crc-nct05197322. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"NEOPRISM-CRC","arms":[{"description":"Patients will one cycle of pembrolizumab 200 mg IV (a cycle is 21 days). Prior to cycle 2 the result of the FOUNDATIONONE®CDx test or FOUNDATIONONE® Liquid CDx should be available and patients will continue their treatment as follows:\n\nTMB-high (defined as ≥20 mutations per Mb) or medium (defined as 6-19 mutations per Mb); FOUNDATIONONE®CDx or FOUNDATIONONE® Liquid CDx test (or MSI-H if FOUNDATIONONE®CDx or FOUNDATIONONE® Liquid CDx test is not evaluable):\n\n* A further two cycles of pembrolizumab 200 mg IV every 21 days\n* Planned surgery to remove the CRC 4 - 6 weeks after last dose of pembrolizumab","label":"Tumour Mutation Burden high or medium (or MSI-High)","type":"OTHER"},{"description":"Patients will one cycle of pembrolizumab 200 mg IV (a cycle is 21 days). Prior to cycle 2 the result of the FOUNDATIONONE®CDx or FOUNDATIONONE® Liquid CDx test should be available and patients will continue their treatment as follows:\n\nTMB-low (defined as ≤5 mutations per Mb); FOUNDATIONONE®CDx or FOUNDATIONONE® Liquid CDx OR if FOUNDATIONONE test and MSI result by PCR are both not evaluable):\n\n• Planned surgery to remove the CRC 4 - 6 weeks after last dose of pembrolizumab","label":"Tumour Mutation Burden low or unevaluable","type":"OTHER"}],"collaborators":["Merck Sharp & Dohme LLC","Sharp","Foundation Medicine","University College London (UCL) Cancer Institute","University of Leeds","University College London Hospitals","Personalis Inc."],"completion_date":{"date":"2029-11-01","type":"ESTIMATED"},"conditions":["Adenocarcinoma of the Colon"],"enrollment":{"count":88,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-14","lead_sponsor":"University College, London","official_title":"NEOPRISM-CRC : Neoadjuvant Pembrolizumab Stratified to Tumour Mutation Burden for High Risk Stage 2 or Stage 3 MMR-deficient Colorectal Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2029-11-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Relapse-free survival","timeFrame":"From registration to any signs or symptoms of the cancer or death assessed up to a maximum of 3 years from surgery date"}],"references":[],"start_date":{"date":"2022-07-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer","url":"https://clinicaltrials.gov/study/NCT05197322"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neoprism-crc-nct05197322"}